SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

计划入组 200,000 人 · 首次发布于 2025 年 9 月 30 日

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

计划入组 21,692 人 · 首次发布于 2026 年 1 月 12 日

Study of Sulphonylurea Synergy With DPP4 Inhibitors

计划入组 30 人 · 首次发布于 2019 年 12 月 10 日

DPP4-Fc

SGLT1/SGLT2/DPP4 Inhibitor(Tonghua Dongbao Pharmaceutical Co., Ltd.)

ALDH Inhibitor (Haimbio)

KalVista Pharmaceuticals

United States

Exelixis, Inc.

United States

Cytokinetics, Incorporated

United States

GLP-1 Receptor Agonists Show Lower Risk for MACE and VTE in Lupus and Type 2 Diabetes Patients Compared to DPP4 Inhibitors

DPP4 Inhibitor Shows Promise in Rejuvenating Lung Stem Cells for Idiopathic Pulmonary Fibrosis

GLP-1 Receptor Agonists Show Survival Benefit in Cancer Patients with Type 2 Diabetes